Rituximab-vemurafenib combination for the treatment of relapsed/Refractory hairy cell leukemia

Basit Öğe Kaydı
dc.authorid0000-0001-9636-4113
dc.authorid0000-0003-0128-6947
dc.contributor.authorSevindik, Ömür
dc.contributor.authorGemici, Aliihsan
dc.contributor.authorMutlu, Yaşa Gül
dc.contributor.authorBalık Aydın, Berrin
dc.contributor.authorÇakır, Aslı
dc.date.accessioned2020-09-28T06:28:32Z
dc.date.available2020-09-28T06:28:32Z
dc.date.issued2020
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Tıbbi Patoloji Ana Bilim Dalı
dc.description.abstractObjective: The management of R/R-HCL is not standardized yet. Patients with HCL universally harbor BRAF mutations, which makes BRAF inhibitors a potential treatment approach. The effi cacy and safety of the BRAF inhibitor Vemurafenib were evaluated both as a single-agent option in two phase 2 trials and also combined with Rituximab in another phase 2 trial. Patients: We have decided to present the fi rst two consecutive patients who achieved a rapid and prolonged response, relapsing after treatment with purine analogues. The fi rst two patients who received a combination of R-V for R/R HCL from the records of our institutional CLPD registry were reported.
dc.identifier.citationSevindik, Ö., Gemici, A., Mutlu, Y. G., Balık Aydın, B. ve Çakır, A. (2020). Rituximab-vemurafenib combination for the treatment of relapsed/Refractory hairy cell leukemia. Clinical Lymphoma, Myeloma & Leukemia içinde (S286-S286. ss.).
dc.identifier.endpageS286
dc.identifier.issn2152-2650
dc.identifier.issn2152-2669
dc.identifier.issueSupplement: 1
dc.identifier.startpageS286
dc.identifier.urihttps://hdl.handle.net/20.500.12511/5870
dc.identifier.volume20
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherCIG Media Group
dc.relation.ispartofClinical Lymphoma, Myeloma & Leukemiaen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectHairy Cell Leukemia
dc.subjectHCL
dc.subjectCombination Therapy
dc.subjectRituximab
dc.subjectVemurafenib
dc.titleRituximab-vemurafenib combination for the treatment of relapsed/Refractory hairy cell leukemia
dc.typeConference Object

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Sevindikk-Omur-2020.pdf
Boyut:
135.02 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Bildiri Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu